@article{article, title = {{EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer}}, publisher = {{Elsevier BV}}, url = {{http://dx.doi.org/10.1093/annonc/mdu269 }}, year = {{2014}}, month = {{7}}, author = {{Heymach JV and Lockwood SJ and Herbst RS and Johnson BE and Ryan AJ}}, doi = {{10.1093/annonc/mdu269}}, volume = {{25}}, journal = {{Annals of Oncology}}, issue = {{10}}, pages = {{1941-1948}}, note = {{Accessed on 2025/08/20}}}